Skip to main content
Top
Published in: Gastric Cancer 4/2013

01-10-2013 | Original Article

Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis

Authors: Sho Takahashi, Michiaki Hirayama, Ganji Kuroiwa, Yutaka Kawano, Kohichi Takada, Tsutomu Sato, Koji Miyanishi, Yasushi Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato

Published in: Gastric Cancer | Issue 4/2013

Login to get access

Abstract

Background

This retrospective study was carried out to compare computed tomographic (CT) gastrography and conventional optical gastroscopy (GS) in order to evaluate the effectiveness of chemotherapy in primary gastric lesions.

Methods

Patients with unresectable advanced and unresected early gastric cancer who had primary lesions and had received chemotherapy were enrolled. For primary lesions, CT gastrography and endoscopic assessment were done after chemotherapy, based on the Japanese Classification of Gastric Carcinoma (JCGC) criteria, 13th edition, and the Response Evaluation Criteria in Solid Tumors (RECIST). For metastatic solid lesions including lymph nodes, CT assessment was done based on the RECIST criteria.

Results

Data from 23 patients were analyzed. With median follow-up of 9.4 months (range 2–23 months), 58 examinations were assessed by GS and CT gastrography. Setting optical endoscopic results as the gold standard, the accuracy of CT gastrography for primary gastric lesions was 77.6 % (45 of 58) (weighted κ = 0.72; P < 0.01) according to the JCGC 13th edition criteria and 90.0 % (52 of 58) (weighted κ = 0.75; P < 0.01) according to the RECIST. When all results were divided into two groups [the non-progressive disease (non-PD) group and PD group], accuracy was 93.1 % (52 of 58) (κ = 0.81; P < 0.01), sensitivity was 100 %, and specificity was 75.0 % (12 of 16). In addition, the predictability of PD was 100 % (12 of 12). The four cases of failure in specification were the following: a case of gastric remnant cancer, a case with insufficient distension of the stomach, a healed case with stenosis and scarring, and a case in which the wrong position had been selected for the examination. The average period until PD was 9.9 months (range 5–18 months), and the concordance period between GS and CT gastrography was 7.2 months in both non-PD and PD cases.

Conclusions

There was good concordance between the evaluations of GS and CT gastrography. CT gastrography exhibited favorable results in accuracy as well as 100 % PD predictability, which implied the possibility of using CT gastrography as a substitute for endoscopic assessments at post-chemotherapy assessments.
Literature
1.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 14th edition. Tokyo: Kanehara; 2010. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 14th edition. Tokyo: Kanehara; 2010.
2.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–4.
3.
go back to reference Kiyohashi A, Kurihara M, Yoshida S, Ohkubo T, Suga S. Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer. Jpn J Clin Oncol. 1993;23:41–5.PubMed Kiyohashi A, Kurihara M, Yoshida S, Ohkubo T, Suga S. Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer. Jpn J Clin Oncol. 1993;23:41–5.PubMed
4.
go back to reference Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, Shimada Y, et al. Response of the primary lesion in gastric cancer to chemotherapeutic trials. Int J Clin Oncol. 1998;3:3–6.CrossRef Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, Shimada Y, et al. Response of the primary lesion in gastric cancer to chemotherapeutic trials. Int J Clin Oncol. 1998;3:3–6.CrossRef
5.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 13th edition. Tokyo: Kanehara; 1999. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma 13th edition. Tokyo: Kanehara; 1999.
7.
go back to reference Ogata I, Komohara Y, Yamashita Y, Mitsuzaki K, Takahashi M, Ogawa M. CT evaluation of gastric lesions with three-dimensional display and interactive virtual endoscopy: comparison with conventional barium study and endoscopy. AJR. 1999;172:1263–70.PubMedCrossRef Ogata I, Komohara Y, Yamashita Y, Mitsuzaki K, Takahashi M, Ogawa M. CT evaluation of gastric lesions with three-dimensional display and interactive virtual endoscopy: comparison with conventional barium study and endoscopy. AJR. 1999;172:1263–70.PubMedCrossRef
8.
go back to reference Inamoto K, Kouzai K, Ueeda T, Marukawa T. CT virtual endoscopy of the stomach: comparison study with gastric fiberscopy. Abdom Imaging. 2005;30:473–9.PubMedCrossRef Inamoto K, Kouzai K, Ueeda T, Marukawa T. CT virtual endoscopy of the stomach: comparison study with gastric fiberscopy. Abdom Imaging. 2005;30:473–9.PubMedCrossRef
9.
go back to reference Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRef Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRef
Metadata
Title
Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis
Authors
Sho Takahashi
Michiaki Hirayama
Ganji Kuroiwa
Yutaka Kawano
Kohichi Takada
Tsutomu Sato
Koji Miyanishi
Yasushi Sato
Rishu Takimoto
Masayoshi Kobune
Junji Kato
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 4/2013
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-012-0217-7

Other articles of this Issue 4/2013

Gastric Cancer 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine